Similar articles

• [3/3 Inhibitors of mTOR (sirolimus and everolimus)].

  Chaumard N, Limat S, Woronoff-Lemsi MC. Chaumard N, et al. Soins. 2007 Sep;(718):63-4. Soins. 2007. PMID: 17970580 French. No abstract available.
• Sirolimus (Rapamune) for transplant rejection.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2000 Feb 7;42(1071):13-4. Med Lett Drugs Ther. 2000. PMID: 10725969 No abstract available.
• Review of symposium. Sirolimus in kidney transplantation.

  Schena FP. Schena FP. Transplantation. 2009 Apr 27;87(8 Suppl):S30-3. doi: 10.1097/TP.0b013e3181a05752. Transplantation. 2009. PMID: 19384185
• Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.

  Diekmann F, Campistol JM. Diekmann F, et al. Nephrol Dial Transplant. 2006 Mar;21(3):562-8. doi: 10.1093/ndt/gfi336. Epub 2005 Dec 16. Nephrol Dial Transplant. 2006. PMID: 16361278 Review. No abstract available.
• Immunoregulation and tolerance.

  Knechtle SJ. Knechtle SJ. Transplant Proc. 2010 Nov;42(9 Suppl):S13-5. doi: 10.1016/j.transproceed.2010.07.039. Transplant Proc. 2010. PMID: 21095443 Review.